

Exploring Opportunities to Reform Antimicrobial Payment and Post-Market Incentives

Marriott Metro Center Washington, DC
January 16, 2020 • 10:00 am – 4:30 pm

Agenda

10:00 am – 10:30 am **On-site registration**

10:30 am – 11:00 am **Welcome and Introduction**

Speaker: Mark McClellan, Director, Duke-Margolis Center for Health Policy

11:00 am – 11:45 am **Session 1 and Opening Discussion: Highlighting US actions on antimicrobial innovation, payment and stewardship**

As the issue of AMR grows more urgent, government organizations have used their authorities to take steps to address the problem. In this session, speakers will provide an overview of domestic efforts to address the threat of AMR, with perspective from the Centers for Disease Control and Prevention (CDC). Discussion will focus on actions that have resulted in measurable impacts and challenges that remain to be addressed.

Speakers:

- Michael Craig, Senior Advisor for Antibiotic Resistance, Antibiotic Resistance Coordination and Strategy Unit, Centers for Disease Control and Prevention
- Mark McClellan, Director, Duke-Margolis Center for Health Policy

11:45 am – 1:00 pm **Session 2: Developing a path to improved and sustainable reimbursement for antibiotics**

Limited return on investment challenges the antimicrobial market. While novel payment approaches may provide more predictable revenue, identifying a feasible path forward can be challenging. Discussion will encompass recent efforts toward reforming payment models, and strategies to engage public- and private-sector stakeholders both domestically and across the globe.

Moderator: Mark McClellan

Panelists:

- Michael Chang, Principal, Adjuvant Capital
- Nick Crabb, Programme Director – Scientific Affairs, National Institute for Health and Care Excellence
- Suzanne Edwards, Economist/Programme Officer, Global AMR R&D Hub
- Monika Schneider, Managing Associate, Duke-Margolis Center for Health Policy

1:00 pm – 1:45 pm

Lunch break

1:45 pm – 3:00 pm

Session 3: Exploring other actions that can contribute to a healthy antimicrobial ecosystem

Providers and payers are developing and implementing new technologies and improved information systems that can enhance the value proposition for utilizing novel antimicrobials. Ensuring the right patient receives the right therapy at the right time requires leveraging rapid diagnostics, ensuring appropriate stewardship, and collecting outcomes and to bolster post-market evidence. Participants will consider how current and future initiatives can improve the adoption, utilization, and sustainability of novel antimicrobials.

Moderator: Mark McClellan**Panelists:**

- Karla Miller, Vice President of Pharmacy Services and Clinical Therapeutics, HCA Healthcare
- Samuel Peasah, Senior Advisor, Center for Value-Based Pharmacy Initiatives, Center for High Value HealthCare, UPMC Insurance Services Division
- Kevin Ronneberg, Vice President and Associate Medical Director, Health Initiatives, HealthPartners
- Soumi Saha, Senior Director of Advocacy, Premier, Inc
- Susan Van Meter, Executive Director, AdvaMedDX

3:00 pm – 3:15 pm

Break

3:15 pm – 4:30 pm

Session 4: Next steps and reflections on the path forward

Progress toward a reinvigorated market for antimicrobials almost certainly depends on the implementation of thoughtful legislative and administrative incentives for investing in and sustaining innovative product pipelines. Panelists will discuss potential paths forward as well as near-term actions that build on the progress of the past year.

Moderator: Mark McClellan**Panelists:**

- Kevin Outtersson, Executive Director, CARB-X, Professor, BU Law
- Jeremy Knox, Policy and Advocacy Lead, Drug-Resistant Infections Programme, Wellcome Trust
- Brenda Huneycutt, Director, Regulatory Innovation, FasterCures
- Robert Horne, Founder, Forest Hill Consulting

4:30 pm

Closing remarks and adjournment